Samstag, 17. April 2021
Navigation öffnen
Anzeige:
Lonsurf
 
JOURNAL ONKOLOGIE – STUDIE

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Rekrutierend

NCT-Nummer:
NCT04191096

Studienbeginn:
Februar 2020

Letztes Update:
12.04.2021

Wirkstoff:
Pembrolizumab, Enzalutamide

Indikation (Clinical Trials):
Prostatic Neoplasms, Hypersensitivity

Geschlecht:
Männer

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Merck Sharp & Dohme Corp.

Collaborator:
-

Studienleiter

Medical Director
Study Director
Merck Sharp & Dohme Corp.

Kontakt

Studienlocations
(3 von 205)

Alaska Clinical Research Center ( Site 0274)
99503 Anchorage
United StatesAbgeschlossen» Google-Maps
Institucion Prestadora de Servicios de Salud Clinica de la Costa LTDA ( Site 2504)
080020 Barranquilla
ColombiaRekrutierend» Google-Maps
Ansprechpartner:
Study Coordinator
Phone: +57353369940
» Ansprechpartner anzeigen
Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu Medycznego im. K. Marcinkowskiego w Pozna
61-848 Poznan
PolandRekrutierend» Google-Maps
Ansprechpartner:
Study Coordinator
Phone: +4861854903
» Ansprechpartner anzeigen
Volga District Medical Center Federal Medical and Biological Agency ( Site 1805)
603074 Nizhny Novgorod
Russian FederationRekrutierend» Google-Maps
Ansprechpartner:
Study Coordinator
Phone: +7 485 249-23-03
» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Brief Summary:

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus ADT

versus placebo plus enzalutamide plus ADT in participants with mHSPC. The primary hypothesis

is that in participants with mHSPC, the combination of pembrolizumab plus enzalutamide plus

ADT is superior to placebo plus enzalutamide plus ADT with respect to 1) radiographic

progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response

Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central

review (BICR) and 2) overall survival (OS).

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Male participants with histologically- or cytologically-confirmed adenocarcinoma of

the prostate without small cell histology

- Has metastatic disease assessed by investigator and verified by BICR by either ≥2 bone

lesions on bone scan and/or visceral disease by computed tomography/magnetic resonance

imaging (CT/MRI)

- Willing to maintain continuous ADT with a LHRH agonists or antagonists during study

treatment or have a history of bilateral orchiectomy

- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed

within 10 days of randomization

- Participants receiving bone resorptive therapy (including, but not limited to,

bisphosphonate or denosumab) must have been on stable doses prior to randomization

- Has adequate organ function

- Has provided newly obtained core or excisional biopsy (obtained within 12 months of

screening) from soft tissue not previously irradiated (samples from tumors progressing

in a prior site of radiation are allowed). Participants with bone only or bone

predominant disease may provide a bone biopsy sample

- Male participants must agree to the following during the intervention period and for

at least 120 days after the last dose of study intervention: Refrain from donating

sperm PLUS either be abstinent from heterosexual intercourse and agree to remain

abstinent OR agree to use contraception, unless confirmed to be azoospermic

- Male participants must agree to use male condom when engaging in any activity that

allows for passage of ejaculate to another person of any sex

Exclusion Criteria:

- Has a known additional malignancy that is progressing or has required active treatment

in the last 3 years

- Has an active autoimmune disease that has required systemic treatment in past 2 years

- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy

- Has undergone major surgery including local prostate intervention (excluding prostate

biopsy) within 28 days prior to randomization and not recovered adequately from the

toxicities and/or complications

- Has a gastrointestinal disorder affecting absorption or is unable to swallow

tablets/capsules

- Has an active infection (including tuberculosis) requiring systemic therapy

- Has a history of (non-infectious) pneumonitis that required steroids or has current

pneumonitis

- Has known active human immunodeficiency virus (HIV), hepatitis B virus (HBV) or

hepatitis C virus (HCV) infection

- Has known or suspected central nervous system (CNS) metastases and/or carcinomatous

meningitis

- Has a history of seizure or any condition that may predispose to seizure

- Has a history of loss of consciousness within 12 months of screening

- Has had myocardial infarction or uncontrolled angina within 6 months prior to

randomization, or has New York Heart Association class III or IV congestive heart

failure or a history of New York Heart Association class III or IV congestive heart

failure

- Has hypotension (systolic blood pressure <86 millimeters of mercury [mmHg]) or

uncontrolled hypertension (systolic blood pressure >170 mmHg or diastolic blood

pressure >105 mmHg) at the screening visit

- Has a history of clinically significant ventricular arrhythmias

- Has hypersensitivity to pembrolizumab and/or enzalutamide and/or any of their

excipients

- Has received prior ADT as neoadjuvant/adjuvant therapy for non-metastatic prostate

cancer for >39 months in duration or within 9 months prior to randomization or with

evidence of disease progression while receiving ADT

- Has had prior treatment with a next generation hormonal agent (eg, abiraterone,

enzalutamide, apalutamide, darolutamide)

- Has received prior therapy with an anti-programmed cell death-1 (anti-PD-1),

anti-programmed cell death-ligand 1 (anti-PD-L1), or anti PD-L2 agent or with an agent

directed to another stimulatory or coinhibitory T-cell receptor

- Has received a live vaccine within 30 days prior to randomization

- Has a "superscan" bone scan

- Has had an allogenic tissue/solid organ transplant

- Is expecting to conceive or father children within the projected duration of the

study, starting with the screening visit through 120 days after the last dose of study

treatment

- Has received any prior pharmacotherapy, radiation therapy or surgery for metastatic

prostate cancer with the following exceptions:

1. Up to 3 months of ADT or orchiectomy with or without concurrent first-generation

antiandrogens, if patient was not treated with docetaxel

2. May have 1 course of palliative radiation or surgical therapy to treat symptoms

resulting from metastatic disease if it was administered at least 4 weeks prior

to randomization

3. For participants with low volume metastatic disease, may have 1 course of

definitive radiotherapy if it was administered at least 4 weeks prior to

randomization

4. Up to 6 cycles of docetaxel therapy with final treatment administration completed

within 2 months of randomization and no evidence of disease progression. In these

participants up to 6 months of ADT permitted

Studien-Rationale

Primary outcome:

1. Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (Time Frame - Up to approximately 77 months):
rPFS is defined as the time from randomization to radiographic progression, or death due to any cause, whichever occurs first. rPFS according to PCWG-modified RECIST 1.1 as assessed by Blinded Independent Central Review will be reported for each study arm.

2. Overall Survival (OS) (Time Frame - Up to approximately 77 months):
OS is defined as the time from randomization to death due to any cause. OS will be reported for each study arm.

Secondary outcome:

1. Time to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST) (Time Frame - Up to approximately 77 months):
TFST is defined as the time from randomization to initiation of the first subsequent anti-cancer therapy or death, whichever comes first. TFST will be reported for each study arm.

2. Time to Symptomatic Skeletal-Related Event (TTSSRE) (Time Frame - Up to approximately 77 months):
TTSSRE is defined as the time from randomization to the first Symptomatic Skeletal-Related Event (SSRE), defined as use of external-beam radiation therapy (EBRT) to prevent or relieve skeletal symptoms, occurrence of new symptomatic pathologic bone fracture (vertebral or nonvertebral), occurrence of spinal cord compression, or tumor-related orthopedic surgical intervention, whichever occurs first. TTSSRE will be reported for each study arm.

3. Time to Prostate-specific Antigen (PSA) Progression (Time Frame - Up to approximately 77 months):
Time to PSA progression is defined as the time from randomization to PSA progression. The PSA progression date is defined as the date of 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, or 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. Time to PSA progression will be reported for each study arm.

4. Time to Radiographic Soft Tissue Progression Per Soft Tissue Rules of Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (Time Frame - Up to approximately 77 months):
Time to radiographic soft tissue progression is defined as the time from randomization to radiographic soft tissue progression, and will be reported for each study arm.

5. Time to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and Opiate Use (Time Frame - Up to approximately 77 months):
TTPP is defined as the time from randomization to pain progression. In this study, pain progression will be assessed by participant responses to Item 3 of the BPI-SF ("worst pain in 24 hours") and by participant opiate use, and will be reported for each study arm.

6. Time from Randomization to Disease Progression as Determined by Investigator Assessment after Next-line of Therapy or Death from Any Cause, Whichever Occurs First (PFS2) (Time Frame - Up to approximately 77 months):
PFS2 is defined as the time from randomization to disease progression as determined by investigator assessment of radiological or clinical progression after next-line of therapy or death from any cause, whichever occurs first. PFS2 will be reported for each study arm.

7. Prostate-specific Antigen (PSA) Response Rate (Time Frame - Up to approximately 77 months):
PSA response rate is defined as the percentage of participants in the analysis population with PSA decline of ≥50% from baseline measured twice at least 3 weeks apart, and will be reported for each study arm.

8. Prostate-specific antigen (PSA) Undetectable Rate (Time Frame - Up to approximately 77 months):
PSA undetectable rate is defined as the percentage of participants in the analysis population with PSA < 0.2 ng/mL during study intervention, and will be reported for each study arm.

9. Objective Response Rate (ORR) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (Time Frame - Up to approximately 77 months):
ORR is defined as the percentage of participants in the analysis population who have a best overall response of either confirmed CR or PR. ORR per PCWG-modified RECIST 1.1 as assessed by Blinded Independent Central Review will be reported for each study arm.

10. Duration of Response (DOR) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (Time Frame - Up to approximately 77 months):
DOR is defined as the time from the earliest date of first documented evidence of confirmed CR or PR until the earliest date of disease progression or death from any cause, whichever occurs first. DOR per PCWG-modified RECIST 1.1 as assessed by Blinded Independent Central Review will be reported for each study arm.

11. Number of Participants Who Experience an Adverse Event (AE) (Time Frame - Up to approximately 77 months):
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE will be reported for each arm.

12. Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE) (Time Frame - Up to approximately 77 months):
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE will be reported for each arm.

Studien-Arme

  • Experimental: Pembrolizumab + Enzalutamide + ADT
    Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
  • Placebo Comparator: Placebo + Enzalutamide + ADT
    Starting on Day 1 of each 21-day cycle, participants receive placebo IV Q3W for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a LHRH agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.

Geprüfte Regime

  • Pembrolizumab (KEYTRUDA® / MK-3475 / ):
    Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
  • Enzalutamide (XTANDI®):
    Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
  • Androgen Deprivation Therapy (ADT):
    Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
  • Placebo:
    Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Krebstherapien können Herz und Gefäße schädigen: Wie schützt man Patienten?
Krebstherapien+k%C3%B6nnen+Herz+und+Gef%C3%A4%C3%9Fe+sch%C3%A4digen%3A+Wie+sch%C3%BCtzt+man+Patienten%3F
©freshidea / Fotolia.de

Die Therapie von Krebserkrankungen hat in den letzten Jahren große Fortschritte gemacht. Verbesserte Operationsmethoden, eine präzisere Strahlenbehandlung und neue Medikamente konnten die Überlebenschancen der Patienten deutlich verbessern. Doch der Fortschritt hat seinen Preis: „Viele Krebstherapien können Herz und Kreislauf schädigen – auch die modernen, zielsicherer an Krebszellen ansetzenden...

Personalisierte Medizin in der Onkologie: Behandlung bestmöglich auf den Patienten zuschneiden

Medikamente möglichst maßgeschneidert auf die spezifischen Merkmale einer Krankheit zuzuschneiden und diese gezielt bei jenen Patienten einzusetzen, denen sie am besten helfen, lautet das Credo der Personalisierten Medizin. Dank vertiefter Kenntnisse über die molekularbiologischen Ursachen von Krankheiten gibt es heute bereits eine Reihe von innovativen diagnostischen Tests, durch die Patienten identifiziert werden...